ArticleAnnals of surgical oncology2020
Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life.
Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Primary Surgery in Metastatic Breast Cancer.European journal of breast health · 2026Article
- Development and internal validation of a multivariable prognostic prediction model in advanced breast cancer patients based on the SEER database.Translational cancer research · 2026Article
- Analysis of the Current Status of De Novo Metastatic Breast Cancer Surgery in China and the USA: A Multicenter Real-World Study.Annals of surgical oncology · 2026Article
- Development and validation of a prognostic model for stage IV breast cancer based on primary tumor resection with machine learning methods: retrospective cohort study.Frontiers in endocrinology · 2026Article
- Review
- Machine learning algorithms for individualized prediction of prognosis in breast cancer liver metastases and the prognostic impact of primary tumor surgery: a multicenter study.Frontiers in endocrinology · 2025Article
- Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapy.Thoracic cancer · 2024Article
- Survival nomogram for patients withCancer pathogenesis and therapy · 2023Article
- The prognostic role of surgery and a nomogram to predict the survival of stage IV breast cancer patients.Gland surgery · 2022Article
- Nomogram Predicts the Role of Primary Tumor Surgery onFrontiers in oncology · 2022Article
- Pure drug nano-assemblies: A facile carrier-free nanoplatform for efficient cancer therapy.Acta pharmaceutica Sinica. B · 2022Review
- Predicting the survival benefit of local surgery in patients aged 70 years or older with stage IV breast cancer: A population-based analysis.Breast (Edinburgh, Scotland) · 2021Article
- Locoregional Therapy in De novo Metastatic Breast Cancer: A Retrospective Cohort Study.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIt was unknown whether surgery for primary tumor would affect the occurrence of local symptoms caused by tumor progression in patients with de novo stage IV breast cancer (BC). Our work attempted to probe the effect of local resection on controlling local symptoms and improving the quality of life in de novo stage IV BC patients.
methodsOur study included patients presenting with de novo stage IV BC at the Cancer Hospital of the Chinese Academy of Medical Sciences from January 2008 to December 2014. In this study, we defined a new term called "local progress/recurrence of symptoms" (LPRS) to refer to the local problems caused by tumor progression/recurrence. All the patients were grouped into surgery and non-surgery groups. The characteristics of the two groups were analyzed by Chi square and Fisher's test. Univariate and multivariate Cox regression models were designed to evaluate independent prognostic factors.
resultsThis study contained 177 patients. The follow-up deadline was April 1, 2019. The median follow-up time was 33 months (range 1-135 months). In included patients, 77 (43.5%) underwent surgery for primary tumors. Primary tumor surgery could reduce the occurrence of LPRS (relative risk/risk ratio (RR = 0.440; 95% CI 0.227-0.852; p = 0.015)) and patients without LPRS had longer OS (45 months vs 29 months, p < 0.001). In addition, patients who had only one symptom had better OS than those who had two or three symptoms (p = 0.0175).
conclusionsThe quality of life in patients with de novo stage IV breast cancer can be improved by reducing the incidence of local symptoms through primary tumor surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.